Shares of Celldex Therapeutics, Inc. (NASDAQ:CLDX) have been assigned an average recommendation of “Hold” from the ten ratings firms that are presently covering the company, Marketbeat.com reports. Three equities research analysts have rated the stock with a sell rating, two have issued a hold rating and five have issued a buy rating on the company. The average twelve-month price target among analysts that have issued a report on the stock in the last year is $6.50.
Several brokerages recently weighed in on CLDX. HC Wainwright restated a “buy” rating and set a $10.00 target price on shares of Celldex Therapeutics in a research note on Tuesday, August 1st. ValuEngine downgraded Celldex Therapeutics from a “sell” rating to a “strong sell” rating in a research note on Friday, September 1st. Zacks Investment Research downgraded Celldex Therapeutics from a “buy” rating to a “sell” rating in a research note on Monday, July 17th. Cantor Fitzgerald restated a “buy” rating and set a $9.00 target price on shares of Celldex Therapeutics in a research note on Tuesday, September 26th. Finally, BidaskClub downgraded Celldex Therapeutics from a “sell” rating to a “strong sell” rating in a research note on Monday, July 24th.
Several hedge funds have recently made changes to their positions in CLDX. Meditor Group Ltd lifted its position in shares of Celldex Therapeutics by 39.9% in the 2nd quarter. Meditor Group Ltd now owns 5,800,000 shares of the biopharmaceutical company’s stock worth $14,326,000 after acquiring an additional 1,654,100 shares during the period. Vanguard Group Inc. lifted its position in shares of Celldex Therapeutics by 16.4% in the 1st quarter. Vanguard Group Inc. now owns 9,066,763 shares of the biopharmaceutical company’s stock worth $32,731,000 after acquiring an additional 1,278,206 shares during the period. Renaissance Technologies LLC lifted its position in shares of Celldex Therapeutics by 42.4% in the 1st quarter. Renaissance Technologies LLC now owns 1,707,927 shares of the biopharmaceutical company’s stock worth $6,166,000 after acquiring an additional 508,217 shares during the period. Dimensional Fund Advisors LP lifted its position in shares of Celldex Therapeutics by 426.4% in the 1st quarter. Dimensional Fund Advisors LP now owns 492,547 shares of the biopharmaceutical company’s stock worth $1,778,000 after acquiring an additional 398,978 shares during the period. Finally, Ameriprise Financial Inc. bought a new stake in shares of Celldex Therapeutics in the 2nd quarter worth approximately $943,000. Institutional investors own 57.07% of the company’s stock.
Shares of Celldex Therapeutics (NASDAQ CLDX) traded up $0.04 during midday trading on Thursday, hitting $2.49. The stock had a trading volume of 1,235,232 shares, compared to its average volume of 1,234,629.
Celldex Therapeutics (NASDAQ:CLDX) last announced its earnings results on Tuesday, August 8th. The biopharmaceutical company reported ($0.23) earnings per share for the quarter, beating the consensus estimate of ($0.28) by $0.05. Celldex Therapeutics had a negative return on equity of 51.87% and a negative net margin of 1,318.94%. The firm had revenue of $3.83 million during the quarter, compared to the consensus estimate of $1.21 million. During the same quarter in the prior year, the company earned ($0.32) EPS. The firm’s revenue for the quarter was up 175.5% compared to the same quarter last year. equities research analysts anticipate that Celldex Therapeutics will post -1.03 earnings per share for the current year.
Celldex Therapeutics Company Profile
Celldex Therapeutics, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of several immunotherapy technologies for the treatment of cancer and other diseases. Its lead drug Rintega (also referred to as rindopepimut and CDX-110) is a therapeutic vaccine, which is meant for the treatment of glioblastoma patients.
What are top analysts saying about Celldex Therapeutics Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Celldex Therapeutics Inc. and related companies.